The Cardiovascular-Renal-Metabolic (CRM) Syndrome Survey in Jordan
JoCRMSSurvey
1 other identifier
observational
10,000
1 country
1
Brief Summary
Cardiovascular-renal-metabolic (CRM) syndrome is defined as a systemic disorder with a collection of related signs and symptoms attributable to the coexistence of multiple cardiovascular, renal and metabolic disease with a common underlying pathophysiology in one individual. Surveying this syndrome in a large population in Jordan aims at studying the risk factors, components and stages of the syndrome, thus helping early screening, diagnosing and treating disease and its risk factors.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 6, 2024
CompletedFirst Posted
Study publicly available on registry
May 14, 2024
CompletedStudy Start
First participant enrolled
July 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2027
Study Completion
Last participant's last visit for all outcomes
December 31, 2027
December 30, 2025
December 1, 2025
1.2 years
May 6, 2024
December 22, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Prevalence of cardiovascular-renal-metabolic syndrome
1. CVD A. Coronary heart disease: Silent and clinical CAD (chronic stable coronary disease, acute coronary disease \[ST-elevation myocardial infarction and non-ST-elevation acute coronary syndrome\]. B. Heart failure. C. Atrial fibrillation. D. Stroke. E. Peripheral artery disease 2. Renal: chronic kidney disease 3. Metabolic: A. Obesity/ B. Diabetes mellitus (DM).
From date of study entry through study completion, an average of 1 year
Secondary Outcomes (1)
Elevated levels of blood markers
From date of study entry through study completion, an average of 1 year
Eligibility Criteria
Consecutive individuals (N=10,000) visiting allocated medical laboratories in North, Center, and South sections of the country during public free blood testing campaigns planned in August 2024 to June 2025.
You may qualify if:
- Adults (age 18 years and above).
- Willing to sign an informed consent.
You may not qualify if:
- None.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Istishari Hospital
Amman, 11184, Jordan
Biospecimen
Centrifuged plasma obtained from peripheral blood sample of the participants
Study Officials
- STUDY DIRECTOR
Ayman Hammoudeh, MD, FACC
Istisjhari Hospital
- STUDY CHAIR
Imad A Alhaddad, MD, FACC
Jordan Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director, Department of Clinical Research
Study Record Dates
First Submitted
May 6, 2024
First Posted
May 14, 2024
Study Start (Estimated)
July 1, 2026
Primary Completion (Estimated)
August 31, 2027
Study Completion (Estimated)
December 31, 2027
Last Updated
December 30, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share